We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us

Download Mobile App

POC Plasmonic COVID-19 Test Uses Sensor Technology to Detect Coronavirus in Less than 45 Minutes

By LabMedica International staff writers
Posted on 08 Feb 2021
Print article
Scientists are developing a rapid point-of-care (POC) plasmonic COVID-19 test based on a cutting-edge sensor technology that would detect SARS-CoV-2 in less than 45 minutes with accuracy, sensitivity, and specificity comparable to the gold standard RT-PCR lab diagnostic.

RNA Disease Diagnostics, Inc. (RNADD; Ontario, Canada) has secured an exclusive global license to the sensor technology jointly owned by the University of Maryland, Baltimore (UMB; Baltimore, MD, USA) and the University of Maryland, Baltimore County (UMBC; Baltimore, MD, USA). The sensor technology will be used to support RNADD's development and manufacture of proprietary molecular disease diagnostic testing kits, enabling the company to quickly and accurately detect multiple infectious diseases, helping to lead to the prevention of their transmission and spread.

The POC plasmonic COVID-19 test currently under development for commercialization would be based on the sensor technology that is designed to accurately and affordably detect infectious diseases in less than 45 minutes. RNADD plans to leverage its proprietary Antisense RNA diagnostic platform across multiple diseases and to create highly accurate, quick, affordable, and minimally invasive disease diagnostic testing kits. The company’s initial focus is to deploy COVID-19 Antisense diagnostic Point of Care (POC) and Home Use Test (HUT) rapid diagnostic testing kits.

"Licensing this promising sensor technology from the universities enables us to advance a diagnostic test that may serve as a future gold standard in accurate and rapid COVID-19 testing. Our hope is that this work contributes to public health as countries begin to reopen following the massive vaccination efforts designed to help with prevention," said Allan Oberman, co-founder and chairman for RNADD.

Related Links:
RNA Disease Diagnostics, Inc.
University of Maryland, Baltimore
University of Maryland

Gold Supplier
Immunoassay Reader
ichroma II
SARS-CoV-2/Influenza A & B/RSV Test
BIOSYNEX® AMPLIQUICK® SARS-COV-2 and Respiratory Triplex
COVID-19 Anitibody Test

Print article


Molecular Diagnostics

view channel
Image: Micrograph of a colorectal adenocarcinoma (Photo courtesy of Wikimedia Commons)

Plasma or Urine Liquid Biopsy Tests May Guide Colorectal Cancer Treatment

A recent paper suggested that liquid biopsy examination of blood or urine could aid in evaluating the effectiveness of therapy for colorectal cancers that had begun to metastasize beyond the site of the... Read more


view channel
Image: Sysmex CN-Series automated blood coagulation analyzer (Photo courtesy of Sysmex Corporation)

Siemens and Sysmex Extend Agreement to Provide One of the Largest Portfolios of Hemostasis Testing Systems and Reagents

Siemens Healthineers (Erlangen, Germany) and Sysmex Corporation (Kobe, Japan) have renewed their long-standing global supply, distributorship, sales and service agreement for a broad portfolio of hemostasis... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.